Pα+ Psychedelic Bulletin #211: AbbVie Enters Psychedelics, 5-MeO-DMT Gets Breakthrough, California Passes AB 1103

AbbVie’s acquisition of Gilgamesh Pharmaceuticals’ lead psychedelic candidate, bretisilocin, marks a major corporate entry into psychedelic drug development, with attention also turning to an associated patent dispute. The bulletin also covers atai and Beckley’s 5-MeO-DMT program receiving Breakthrough Therapy Designation and highlights funding and FDA-related progress signals for psychedelic developers. On the policy front, California’s Newsom signs AB 1103, aimed at easing a review bottleneck for psychedelic research, with the bulletin framing these shifts as interconnected pressure and momentum across industry, regulators, and study access.